Antigen-specific immunotherapy via delivery of tolerogenic dendritic cells for multiple sclerosis.

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system resulting from loss of immune tolerance. Many disease-modifying therapies for MS have broad immunosuppressive effects on peripheral immune cells, but this can increase risks of infection and attenuate vaccine-elicited immunity. A more targeted approach is to re-establish immune tolerance in an autoantigen-specific manner. This review discusses methods to achieve this, focusing on tolerogenic dendritic cells. Clinical trials in other autoimmune diseases also provide learnings with regards to clinical translation of this approach, including identification of autoantigen(s), selection of appropriate patients and administration route and frequency.
Competing Interests: Declaration of competing interest AWP is on the scientific advisory board of Bioinformatics Solutions Inc., Grey Wolf Therapeutics and Evaxion Biotech, is a share holder of Evaxion Biotech and co-founder of Resseptor Therapeutics. None had any influence on this study. VL, MB, TK have no conflicts of interest to declare.
(Copyright © 2024. Published by Elsevier B.V.)